Macrogenics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Macrogenics (MGNX).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

4Buy

7Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$8Upside to Avg. PT+100.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 17, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$9→$11
Apr 20, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$4→$6
Apr 10, 2026	B. Riley Securities	Mayank Mamtani	Upgrade	Neutral→Buy	$3→$9
Mar 10, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$3→$4
Nov 3, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	$2
Sep 17, 2025	Barclays	Etzer Darout	Assumes	Overweight	$3
Aug 15, 2025	Leerink Partners	—	PT Cut	Outperform	$8→$5
May 20, 2025	B. Riley Securities	Mayank Mamtani	PT Cut	Neutral	$5→$3
May 14, 2025	Stifel	Stephen Willey	PT Cut	Hold	$6→$5
May 14, 2025	Barclays	Peter Lawson	PT Cut	Overweight	$8→$3
Mar 25, 2025	HC Wainwright & Co.	Robert Burns	PT Cut	Neutral	$4→$2
Nov 7, 2024	JMP Securities	Silvan Tuerkcan	Downgrade	Market Outperform→Market Perform	—
Nov 6, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	$4
Sep 18, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	$4
Aug 21, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	$4
Aug 15, 2024	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$16→$14
Aug 7, 2024	Stifel	Stephen Willey	PT Cut	Hold	$7→$6
Aug 7, 2024	BMO Capital	Etzer Darout	PT Cut	Market Perform	$8→$5
Aug 1, 2024	BTIG	Kaveri Pohlman	Downgrade	Buy→Neutral	—
Aug 1, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Buy and raises the price target from $9 to $11.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6

Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $4 to $6.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4

Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $3 to $4.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $2 price target.

Benzinga Newsdesk

4 Analysts Assess Macrogenics: What You Need To Know

Benzinga Insights

PRO
B. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3

B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Neutral and lowers the price target from $5 to $3.

Benzinga Newsdesk

Macrogenics Inc

Macrogenics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4

PRO
HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target

4 Analysts Assess Macrogenics: What You Need To Know

PRO
B. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3

People Also Watch

People Also Watch

Macrogenics Inc

Macrogenics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

PROBarclays Maintains Overweight on Macrogenics, Raises Price Target to $6

PROBarclays Maintains Overweight on Macrogenics, Raises Price Target to $4

PROHC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target

4 Analysts Assess Macrogenics: What You Need To Know

PROB. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3

People Also Watch

People Also Watch

PRO
B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4

PRO
HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target

PRO
B. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3